An additional bispecific, humanized IgG1 antibody that is underneath investigation is zenocutuzumab (MCLA-128), which functions via two unbiased mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 features through a ‘dock and block’ system whereby one arm from the antibody binds HER2 are